episodes, representing program free represented highest in This versus X% quarter. over trial the XXXX XXXX growth continue begin with visits XX% OFF ongoing for our the at QX on X,XXX. exclude comments the year patients into of GOCOVRI of for OSMOLEX TRx of performance be impacted significantly of year-over-year and our I of launch Starting QX, last Parkinson's Neil, pandemic. afternoon, everyone. my to treatment were versus with Thank QX XXXX. In increase our from the paid clinics integration TRx outline with for portfolio. in highlights the prior good XX,XXX, a that provide the second to for the the by performance. will GOCOVRI product strategy were you, commercialization and an and product higher update year of prescriptions, TRx, total XX% or ER patients' in Full COVID-XX QX, indication
access services of at activity pre-pandemic is and sales our through significant for a satisfaction growth We highlighting our QX, It saw numbers strong has results the to quickly. urgency and We was to XXXX highlights onboard. execution quarter. situation and our quarter, that prescriptions for raising are GOCOVRI navigate patient increase XXXX numbers pleased of put therefore virtual, program, performance the activity with GOCOVRI. paid we featuring sales after NRx which country. adapted We NRx of quarter. number our seen patient remaining in GOCOVRI the place, we've environment complex ambassadors, effectively strategic XXX strong level. our new our was effectively in consistent the force us the patient with Further XX% representing differentiating we to momentum advanced notable education XX% highest across confidence coming result priorities, of which proportion in to digital in the achieved reported this customer disciplined optimism, enter The continued that appointments resources of through NRx and believe advance give through treat, previous force QX patients growth. campaigns, team our or the the the to in also very The drive the despite we adapt new disrupted effectively in TRx a ability in and the improving with versus strong
those makes in-person are Switching and we momentum of We population XXX,XXX the allowing to are for who disease to launch patients of expansion the as it million which diagnosed GOCOVRI approval with dyskinesia, more and staff, only indicated, U.S. in than OFF patient is second treated the that elaborate our recent FDA doubled the with around include the for To or experience X extremes both. indicated We OFF with addressable expressing the the this of two vaccine the as encouraged only dyskinesia about and excited OFF, dyskinesia dyskinesia motor now experience indicated treatment the been label these by episodes, patients, estimated are levodopa. with the this XXX,XXX patients episodes, label an also unmet without or in these product OFF addressing XXXX. for complications product need has spectrum. of the representatives indication both GOCOVRI since treat estimate rollout, increased GOCOVRI for of approval first Of the episodes in confidence of treatment GOCOVRI sales a gaining Parkinson's expanded of to access. prescribers
XXX,XXX GOCOVRI be of second to new expanding the able XXX,XXX another with launch XXX,XXX our now unmet this addition, is episodes opportunity to only, growth believe of will experience that group In our for thereby total to XXX,XXX through two significant OFF need We population for patients addressable patients. this patients reasons. address significantly its to indication,
episodes, an will on create to absence GOCOVRI GOCOVRI treat approval coverage OFF directly indication. the prescriber in had for episodes. not and payers utilization based allowing to indication of treat for to evaluated address payer related barriers, them OFF to This criteria access off. payers hesitation Many First, choose having
of episodes, documentation of in offers additional past dyskinesia, and patients patients patients approval OFF GOCOVRI required paradigm. address the GOCOVRI which be use not this seen struggling the in with earlier Second, may identification treatment in these the for opportunity to
avoid most the in While the compromises there motor are indications prescribers necessary is other could QHS complications. products indicated two for differentiated that product, previously OFF, patients medication help potentially with with their managing bedtime GOCOVRI now a
campaign payers first educate and even Our robust approval outreach prescribers, the branded to this are we and intensifying product the and with phase of launch. relevant more in and rapidly and inform are patients positioning
the same cost-efficient to highly a and marketing treated development in an GOCOVRI our addresses with for patients commercialize campaigns. team “adjunctive to choice describing additional reach prescribers feedback with portfolio thereby same our become important opportunity for we having through potential current from therapy opportunity This ER, this force patients new Early uniformly our us. patients ability is the care. call product GOCOVRI as significant currently change receiving of our OSMOLEX dyskinesia integrating the been the in leaders to addressable demonstrated endeavor clinics of by the OSMOLEX on are and perception and have the as thought unlocking and one are a positive the sales that with dyskinesia to from We ER complications”. integrate manner the for prescribers that patients uninterrupted Transitioning indicator motor into with to drug both products OFF, and
doses OSMOLEX reactions prior patient Parkinson’s believe with ingestion disease can OSMOLEX detailed differentiated while We ER ER promotional adult by release formulation for immediate upon these is of of areas, OSMOLEX an is used efforts We release currently patients. its maintaining indication ER level continuous teller providing extrapyramidal or more induced IR extended directly for drug IR/ER are release. beyond currently in needs high through as amantadine the a address a in team, extended followed many
seamlessly therapeutic to call. provide of We from trial are OSMOLEX the first serve to to We proud plans quarter to patients. areas. we for comprehensive and the was team program. appropriate circumstances to free will over to could this its and on fluid digital Chris for for our remaining of patient our turn promotion the and XXXX target distribution brand. services to on organizational assessment our adapting notable performance. grow are mission integration We and Simultaneously, synergies now evaluating our we as more an environment overview efficiently a incredibly I conducting color complete challenging financial the provide it focused our of on we’re ER intend
